AstraZeneca stock (US6549022043): Beats Q1 Estimates, Analysts Raise Targets

AstraZeneca has delivered better-than-expected first-quarter results, posting earnings per share of $2.58 and revenue of $15.29 billion, both surpassing analyst consensus estimates, according to MarketBeat as of May 11, 2026. The pharmaceutical giant's strong operational performance has reinforced investor confidence and triggered multiple analyst rating adjustments.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

AstraZeneca: Core business model

AstraZeneca operates as a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across oncology, cardiovascular, respiratory, and immunology segments. The company serves patients in more than 100 countries and maintains research and development operations alongside manufacturing and distribution networks. US investors gain exposure to a diversified pharmaceutical portfolio with significant market presence in the American healthcare system, where oncology and specialty care represent major revenue streams.

Main revenue and product drivers for AstraZeneca

The company's growth is anchored in its oncology franchise, which includes treatments for various cancer types, alongside respiratory medications and cardiovascular therapies. Recent product launches and label expansions have broadened the addressable market for existing assets. The first-quarter revenue of $15.29 billion reflects broad-based growth across therapeutic areas, demonstrating the strength of both established and newer products in the portfolio.

Analyst sentiment and price targets

Wall Street analysts have raised their outlook on AstraZeneca following the earnings beat. According to research from six equities analysts, the average twelve-month price target stands at £153.33, with a high forecast of £180 and a low of £115, according to MarketBeat as of May 8, 2026. Citigroup recently increased its target price to £180, signaling confidence in the company's near-term trajectory. The consensus rating reflects a Moderate Buy stance, with five buy ratings and no strong buy ratings among covered analysts.

Conclusion

AstraZeneca's first-quarter earnings beat and subsequent analyst upgrades underscore the company's operational momentum and market position within the global pharmaceutical sector. The 14.91% upside forecast from current levels reflects analyst confidence in the company's ability to sustain growth across its therapeutic portfolios. For US investors, AstraZeneca represents exposure to a diversified pharmaceutical business with established market presence and a pipeline of specialty care products.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.